GlobeNewswire
Source: Penwest Pharmaceuticals Co.
In the Phase Ib trial, the drug was well tolerated by subjects, and no serious adverse events were reported. There was a dose-dependent increase in exposure approaching steady state within 2-4 days following repeat-dosing, and a maximum tolerated dose was established.
Plans to Advance A0001 Into Phase IIa Trials in Patients in Second Half of 2009
http://www.penw.com/
http://health.groups.yahoo.com/group/FA_babelFAmily/message/3058
Thursday, July 16, 2009
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment